These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

657 related items for PubMed ID: 22658967

  • 21. Immunogenicity and safety of monovalent influenza A (H1N1) 2009 in HIV-infected Thai children.
    Phongsamart W, Sirisanthana V, Wittawatmongkol O, Maleesatharn A, Sudjaritruk T, Chearskul P, Aurpibul L, Sirisanthana T, Chokephaibulkit K.
    Vaccine; 2011 Nov 03; 29(47):8705-11. PubMed ID: 21893147
    [Abstract] [Full Text] [Related]

  • 22. Maternal immune response and neonatal seroprotection from a single dose of a monovalent nonadjuvanted 2009 influenza A(H1N1) vaccine: a single-group trial.
    Tsatsaris V, Capitant C, Schmitz T, Chazallon C, Bulifon S, Riethmuller D, Picone O, Poulain P, Lewin F, Lainé F, Jacqz-Aigrain E, Aboulker JP, Launay O, Inserm C09-33 PREFLUVAC (Immunogenicity and Safety of an Inactivated Nonadjuvanted A[H1N1v] Influenza Vaccine in Pregnant Women) Study Group.
    Ann Intern Med; 2011 Dec 06; 155(11):733-41. PubMed ID: 22147712
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy.
    Pariani E, Boschini A, Amendola A, Poletti R, Anselmi G, Begnini M, Ranghiero A, Cecconi G, Zanetti AR.
    Vaccine; 2011 Nov 15; 29(49):9209-13. PubMed ID: 21974995
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Immune response to 2009 pandemic H1N1 influenza virus A monovalent vaccine in children with cancer.
    Yen TY, Jou ST, Yang YL, Chang HH, Lu MY, Lin DT, Lin KH, Huang LM, Chang LY.
    Pediatr Blood Cancer; 2011 Dec 15; 57(7):1154-8. PubMed ID: 21425448
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A clinical study to assess the immunogenicity and safety of a monovalent 2009 influenza A (H1N1) vaccine in an area with low-level epidemics of pandemic influenza.
    Kung HC, Huang KC, Kao TM, Lee YC, Chang FY, Wang NC, Liu YC, Lee WS, Liu HJ, Chen CI, Chen CH, Huang LM, Hsieh SM.
    Vaccine; 2010 Oct 21; 28(45):7337-43. PubMed ID: 20817013
    [Abstract] [Full Text] [Related]

  • 29. Poor seroprotection but allosensitization after adjuvanted pandemic influenza H1N1 vaccine in kidney transplant recipients.
    Fairhead T, Hendren E, Tinckam K, Rose C, Sherlock CH, Shi L, Crowcroft NS, Gubbay JB, Landsberg D, Knoll G, Gill J, Kumar D.
    Transpl Infect Dis; 2012 Dec 21; 14(6):575-83. PubMed ID: 22999005
    [Abstract] [Full Text] [Related]

  • 30. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children.
    Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D.
    Vaccine; 2011 Dec 09; 30(1):35-41. PubMed ID: 22063386
    [Abstract] [Full Text] [Related]

  • 31. Assessment of the immunogenicity and safety of varying doses of an MF59®-adjuvanted cell culture-derived A/H1N1 pandemic influenza vaccine in Japanese paediatric, adult and elderly subjects.
    Fukase H, Furuie H, Yasuda Y, Komatsu R, Matsushita K, Minami T, Suehiro Y, Yotsuyanagi H, Kusadokoro H, Sawata H, Nakura N, Lattanzi M.
    Vaccine; 2012 Jul 13; 30(33):5030-7. PubMed ID: 22472791
    [Abstract] [Full Text] [Related]

  • 32. Long-term immunogenicity of an AS03-adjuvanted influenza A(H1N1)pdm09 vaccine in young and elderly adults: an observer-blind, randomized trial.
    Yang WH, Dionne M, Kyle M, Aggarwal N, Li P, Madariaga M, Godeaux O, Vaughn DW.
    Vaccine; 2013 Sep 13; 31(40):4389-97. PubMed ID: 23856331
    [Abstract] [Full Text] [Related]

  • 33. Compatibility of ASO3-adjuvanted H1N1pdm09 and seasonal trivalent influenza vaccines in adults: results of a randomized, controlled trial.
    Scheifele DW, Ward BJ, Dionne M, Vanderkooi OG, Loeb M, Coleman BL, Li Y, PHAC/CIHR Influenza Research Network (PCIRN).
    Vaccine; 2012 Jul 06; 30(32):4728-32. PubMed ID: 22652402
    [Abstract] [Full Text] [Related]

  • 34. Pandemic whole-virion, Vero-cell-derived, adjuvant-free influenza A H1N1 vaccine in patients with solid tumors and hematologic malignancies receiving concurrent anticancer treatment: Immunogenicity, tolerability, and acceptability during the pandemic situation.
    Lagler H, Tobudic S, Ramharter M, Elandt K, Sperr WR, Redlberger-Fritz M, Popow-Kraupp T, Jäger U, Zielinski CC, Burgmann H.
    Vaccine; 2012 Nov 06; 30(48):6864-70. PubMed ID: 22989690
    [Abstract] [Full Text] [Related]

  • 35. Priming with AS03 A-adjuvanted H5N1 influenza vaccine improves the kinetics, magnitude and durability of the immune response after a heterologous booster vaccination: an open non-randomised extension of a double-blind randomised primary study.
    Leroux-Roels I, Roman F, Forgus S, Maes C, De Boever F, Dramé M, Gillard P, van der Most R, Van Mechelen M, Hanon E, Leroux-Roels G.
    Vaccine; 2010 Jan 08; 28(3):849-57. PubMed ID: 19835828
    [Abstract] [Full Text] [Related]

  • 36. Immunogenicity and tolerability of an inactivated and adjuvanted pandemic H1N1 influenza vaccine, in HIV-1-infected patients.
    Tremblay CL, Rouleau D, Fortin C, Toma E, Sylla M, Cyr L, Cote S, Baz M, Sampalis J, Trautman L, Sékaly RP, Boivin G.
    Vaccine; 2011 Feb 04; 29(7):1359-63. PubMed ID: 21185423
    [Abstract] [Full Text] [Related]

  • 37. Host immune response to A(H1N1)pdm09 vaccination and infection: a one-year prospective study on six cohorts of subjects.
    Liu W, Ma MJ, Tang F, He C, Zhang XA, Jiang LF, Xin DS, Hu CY, Looman C, Cao WC.
    Vaccine; 2012 Jul 06; 30(32):4785-9. PubMed ID: 22633868
    [Abstract] [Full Text] [Related]

  • 38. An adjuvanted, low-dose, pandemic influenza A (H5N1) vaccine candidate is safe, immunogenic, and induces cross-reactive immune responses in healthy adults.
    Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, Leroux-Roels G, Pichon S, Kusters I.
    J Infect Dis; 2008 Sep 01; 198(5):642-9. PubMed ID: 18576945
    [Abstract] [Full Text] [Related]

  • 39. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice.
    Caillet C, Piras F, Bernard MC, de Montfort A, Boudet F, Vogel FR, Hoffenbach A, Moste C, Kusters I.
    Vaccine; 2010 Apr 19; 28(18):3076-9. PubMed ID: 20193791
    [Abstract] [Full Text] [Related]

  • 40. [A survey of levels of antibodies against influenza viruses in the population of Wuxi City].
    You FX, Sun N, Ma GY, Wang MM, Sa D, Shi C, Wu JL, Lin X, Xiao Y, Qian YH, Jiang Y, Xie J, Ji YY, Guan HX.
    Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2011 Oct 19; 25(5):351-4. PubMed ID: 22338222
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 33.